Praxis shares climbed another 40% on a pair of positive updates on two different drugs. Elsewhere, Bristol Myers’ Breyanzi was cleared for its fifth cancer indication and AstraZeneca expanded a rare ...
SciNeuro Pharmaceuticals represents the latest in a string of Arch investments directed at the nervous system, a notoriously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback